Rethinking Medical Aid in Dying: What Does It Mean to 'Do No Harm?'

Dallas R Lawry
{"title":"Rethinking Medical Aid in Dying: What Does It Mean to 'Do No Harm?'","authors":"Dallas R Lawry","doi":"10.6004/jadpro.2023.14.4.5","DOIUrl":null,"url":null,"abstract":"<p><p>Medical aid in dying is the act of prescribing lethal medications to a consenting patient who can self-ingest them with the intent of hastening their death. A majority of patients who utilize medical aid in dying are patients with terminal cancer. As oncology patients continue to choose deaths most suitable to them, it is critical that advanced practitioners in oncology be knowledgeable regarding this end-of-life decision. With 40 states denying patients access to medical aid in dying, the purpose of this end-of-life care review is not to persuade for or against medical aid in dying, active euthanasia, or other forms of dying with dignity, but rather to shed light on patient decisions and available end-of-life options for patients where medical aid in dying is not honored. One author has succinctly named this era as \"Dying in the Age of Choice,\" and therefore the purpose of this article is to present the current state of medical aid in dying. The article presents case studies for the reader, as well as a comparison of California's statistics with the national average. Much like other controversial subjects that intersect morality, religion, and Hippocratic medical ethics, practitioners in the healing arts must remain unbiased and honor the wishes of patients even when they differ from their own. In serving the population with the highest utilization of medical aid in dying, advanced practitioners in oncology should be familiar with the legal specifications in their state or be abreast of solutions for guiding patients through end of life in the states where medical aid in dying remains illegal.</p>","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"14 4","pages":"307-316"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1d/03/jadpro-14-307.PMC10258856.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Advanced Practitioner in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.6004/jadpro.2023.14.4.5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Medical aid in dying is the act of prescribing lethal medications to a consenting patient who can self-ingest them with the intent of hastening their death. A majority of patients who utilize medical aid in dying are patients with terminal cancer. As oncology patients continue to choose deaths most suitable to them, it is critical that advanced practitioners in oncology be knowledgeable regarding this end-of-life decision. With 40 states denying patients access to medical aid in dying, the purpose of this end-of-life care review is not to persuade for or against medical aid in dying, active euthanasia, or other forms of dying with dignity, but rather to shed light on patient decisions and available end-of-life options for patients where medical aid in dying is not honored. One author has succinctly named this era as "Dying in the Age of Choice," and therefore the purpose of this article is to present the current state of medical aid in dying. The article presents case studies for the reader, as well as a comparison of California's statistics with the national average. Much like other controversial subjects that intersect morality, religion, and Hippocratic medical ethics, practitioners in the healing arts must remain unbiased and honor the wishes of patients even when they differ from their own. In serving the population with the highest utilization of medical aid in dying, advanced practitioners in oncology should be familiar with the legal specifications in their state or be abreast of solutions for guiding patients through end of life in the states where medical aid in dying remains illegal.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
反思临终医疗救助:无伤害 "意味着什么?
临终医疗救助是指在病人同意的情况下,为其开具致命药物,让其自行服用,以加速其死亡。大多数使用临终医疗救助的患者都是晚期癌症患者。随着肿瘤患者继续选择最适合自己的死亡方式,肿瘤科的高级执业医师必须了解这种临终决定。美国有 40 个州拒绝为患者提供临终医疗救助,因此本篇临终关怀综述的目的并不是劝说患者支持或反对临终医疗救助、积极安乐死或其他形式的有尊严的死亡,而是要阐明在临终医疗救助不被接受的情况下,患者的决定和可用的临终选择。一位作者简明扼要地将这个时代命名为 "选择时代的死亡",因此本文的目的是介绍临终医疗救助的现状。文章为读者提供了案例研究,并将加利福尼亚州的统计数据与全国平均水平进行了比较。与其他交织着道德、宗教和希波克拉底医学伦理的争议性话题一样,从事治疗艺术的从业者必须保持公正,尊重病人的意愿,即使这些意愿与他们自己的意愿不同。在为使用临终医疗救助最多的人群提供服务时,肿瘤学高级执业医师应熟悉所在州的法律规范,或了解在临终医疗救助仍属非法的州指导病人完成生命终结的解决方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Diversity, Equity, and Inclusion in Multiple Myeloma: A Call to Action A Real-World Evidence Primer for Advanced Practice Providers: Integrating P-Reality X Into Shared Decision-Making for People With HR+/HER2− Metastatic Breast Cancer Impact of an Oncology Clinical Pharmacist Intervention on Clinical Trial Enrollment in The US Oncology Network’s MYLUNG Consortium Beyond Standard Endocrine Therapy: A New Adjuvant Treatment in High-Risk Early Breast Cancer Evaluating the User-Perceived Benefit of a Virtual Lung Cancer Patient Education and Support Community: LVNG With Lung Cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1